Arovella Therapeutics LimitedASX: ALA

Research Agreement with University of North Carolina

· Issued by Arovella Therapeutics Limited

Filed with ASX · · 2 pages · English

Summary by 6ix AI

The SRA will run for one year and involves joint ownership of any intellectual property developed during the research. Arovella's CEO expressed enthusiasm about this partnership and the recruitment of a talented scientist to advance their CAR-iNKT cell programs targeting solid tumours.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Arovella Therapeutics Limited on 6ix

Earlier from Arovella Therapeutics

Later from Arovella Therapeutics

All Arovella Therapeutics news releases